Drugs / MiraMSC-FS-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07705464 | Dec 2026 → Jun 2028 expected | — | Miracle Biomedical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MiraMSC-FS-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07705464 ↗ |
| Modality | Cell therapy | “allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs)” NCT07705464 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07705464 ↗ |